Scholarlink

<p>Immune checkpoint inhibitors are now an integral part of cancer treatment, and cutaneous side effects are common. We report the case of a&#xa0;40-year-old woman who developed purpura pigmentosa progressiva (PPP) in temporal association with pembrolizumab. This case report describes PPP as a&#xa0;rare potential adverse effect of immune checkpoint inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Purpura pigmentosa progressiva unter Immuncheckpoint-Inhibitor-Therapie mit Pembrolizumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月12日

查看全文
  • Annia Cherrez-Eschrich,
  • Amrei Dilling,
  • Kamran Ghoreschi,
  • Alexander Nast

摘要

Immune checkpoint inhibitors are now an integral part of cancer treatment, and cutaneous side effects are common. We report the case of a 40-year-old woman who developed purpura pigmentosa progressiva (PPP) in temporal association with pembrolizumab. This case report describes PPP as a rare potential adverse effect of immune checkpoint inhibitors.